Newsletter of the NIH Rare Diseases Clinical Research Network
Volume 2, Issue 1. Spring 2011

www.RareDiseasesNetwork.org

In This Issue

Welcome

Spotlight on an RDCRN Consortium: CINCH

How Does A Rare Disease Consortium Work?

Urea Cycle Disorders Consortium Benefits from CTSA Leverage

Coalition of Patient Advocacy Groups (CPAG) in the Spotlight

The Office of Rare Diseases Research (ORDR)

RDCRN Opens 30 New Studies for Patient Accrual

About Spotlight

Past Issues

 

Rare Diseases Headlines:

NIH Researchers Identify genetic cause of new vascular disease – Rare disease is the first discovered in Undiagnosed Diseases Program
>> More

Statement Issued from the 2nd Meeting of the International Rare Diseases Research Consortium
>> More

Featured Event:

Rare Diseases Day 2011
>> More

Spotlight Announcements / Calendar of Events

Joubert Syndrome Biennial Conferences: Advancing Translational Ciliopathy Research, July 13, 2011 - July 16, 2011

International Meeting on Genetic Syndromes of the Ras/MAPK Pathway, July 29, 2011 - July 31, 2011

End of Life Palliative Care National Science Summit, August 10, 2011 - August 12, 2011

>> View More News and Events

CPAGCPAG in the Spotlight

The Coalition for Patients Advocacy Groups (CPAG) has been a critical pillar for the support of the Rare Diseases Clinical Research Network (RDCRN). CPAG has been very active this year in three main work arenas: 1) Communications, which focuses primarily on internal communications within the group; 2) Outreach, which champions the cause of the Rare Diseases Clinical Research Network (RDCRN) from the CPAG perspective, especially to increase awareness outside of the current network; 3) Education, the component of CPAG which takes responsibility for coordinating teleconferences  and meetings.

Study participation increases when patients are educated within their trusted advocacy community about their critical role in advancing research.

Supporting the rare disease research enterprise as full partners in the RDCRN is the unique and crucial role of CPAG. The RDCRN investigators recognize the critical importance of patient advocacy and consider this growing partnership to be one of the most important legacies of the RDCRN Program. In addition, it is hoped that the success of this relationship between the physician-investigators and the CPAG volunteers will be a model of how such partnerships can lead to a more open and  informed research process The Office of Rare Diseases Research (ORDR) has been very instrumental in keeping CPAG members updated on RDCRN and NIH issues in monthly calls and email communications.

CPAG encourages you to be actively involved your advocacy organizations.

Some of the reasons to do so are:

Why You Need Patient Advocacy

We Put The Face On The Syndrome or Disease ~ You Put the Hope in Our Hearts

Thank you for being our partner in making the world of rare diseases a better place.

CPAG Co-Chairs: